Late-stage trial data showed 90% effectiveness in preventing COVID-19 infection
Pfizer, alongside the German BioNTech, made a bold statement earlier today that impressed the markets.
According to the report published about their late-stage vaccine trial, their coronavirus vaccine is more than 90% effective in preventing COVID-19. The 90% effectiveness took people by storm, as scientists and researchers were hoping for a COVID-19 vaccine to be at least 75% effective.
The results came after an interim efficacy analysis that was conducted by an independent Data Monitoring Committee. The participants showed improvements one week after the administration of the second dose. Following the data, protection from COVID-19 is possible 28 days after the first vaccination. The whole procedure consists of two doses.
Even though the first results are promising, data regarding safety and various aspects of the vaccine are still being collected.
Wall Street was more than thrilled when hearing the news. USA30 surged 5.2%, while USA500 jumped 3.4%.
Sources: cnbc.com
This information is prepared for general circulation. It does not regard to the specific investment objectives, financial situation or the particular needs of any recipient.
You should independently evaluate each financial product and consider the suitability of such a financial product, by taking into account your specific investment objectives, financial situation or particular needs, and by consulting an independent financial adviser as needed, before dealing in any financial products mentioned in this document.
This information may not be published, circulated, reproduced or distributed in whole or in part to any other person without the Company’s prior written consent. Past performance is not always indicative of likely or future performance. Any views or opinions presented are solely those of the author and do not necessarily represent those of za.capex.com
